Parrish Capital LLC Has $2.93 Million Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

Parrish Capital LLC lowered its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 14.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 97,153 shares of the company’s stock after selling 16,584 shares during the period. Teva Pharmaceutical Industries comprises 2.6% of Parrish Capital LLC’s portfolio, making the stock its 4th largest holding. Parrish Capital LLC’s holdings in Teva Pharmaceutical Industries were worth $2,926,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Menora Mivtachim Holdings LTD. raised its position in Teva Pharmaceutical Industries by 1.1% in the third quarter. Menora Mivtachim Holdings LTD. now owns 38,920,294 shares of the company’s stock worth $786,190,000 after purchasing an additional 427,000 shares in the last quarter. Victory Capital Management Inc. lifted its stake in Teva Pharmaceutical Industries by 2.0% during the third quarter. Victory Capital Management Inc. now owns 2,360,762 shares of the company’s stock worth $47,687,000 after purchasing an additional 45,395 shares during the period. Legal & General Group Plc boosted its holdings in Teva Pharmaceutical Industries by 6.8% during the fourth quarter. Legal & General Group Plc now owns 3,608,387 shares of the company’s stock valued at $112,618,000 after purchasing an additional 228,189 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in shares of Teva Pharmaceutical Industries by 8.0% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,082,578 shares of the company’s stock valued at $33,506,000 after purchasing an additional 80,106 shares during the period. Finally, Norges Bank bought a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter valued at approximately $1,098,060,000. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $34.55 on Friday. Teva Pharmaceutical Industries Ltd. has a 1 year low of $14.99 and a 1 year high of $37.35. The firm has a 50 day moving average of $33.96 and a 200-day moving average of $32.55. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70. The stock has a market capitalization of $39.73 billion, a P/E ratio of 25.98, a price-to-earnings-growth ratio of 4.23 and a beta of 0.86.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. The business had revenue of $3.98 billion for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%. As a group, sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 1.97 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on TEVA. Barclays increased their target price on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Truist Financial upped their price target on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Piper Sandler reiterated an “overweight” rating and set a $42.00 price objective (up from $41.00) on shares of Teva Pharmaceutical Industries in a research note on Thursday, April 30th. JPMorgan Chase & Co. lifted their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Finally, Bank of America boosted their target price on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 9th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $41.78.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, insider Mark Sabag sold 144,180 shares of the business’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $34.99, for a total value of $5,044,858.20. Following the transaction, the insider owned 80,760 shares of the company’s stock, valued at approximately $2,825,792.40. The trade was a 64.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Amir Weiss sold 10,679 shares of the stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $36.00, for a total value of $384,444.00. Following the sale, the chief accounting officer owned 20,016 shares in the company, valued at $720,576. The trade was a 34.79% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 465,931 shares of company stock valued at $16,332,989. Insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.